within Pharmacolibrary.Drugs.ATC.C;

model C01DA02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.019666666666666666,
    adminDuration  = 600,
    adminMass      = 0.5,
    adminCount     = 1,
    Vd             = 0.0033,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Glyceryl trinitrate (GTN), also known as nitroglycerin, is a vasodilator used primarily for the treatment and prevention of angina pectoris (chest pain) and heart failure. It acts by releasing nitric oxide, leading to relaxation of vascular smooth muscle. Glyceryl trinitrate is still widely used and is approved for acute and chronic management of angina and for use in certain acute cardiovascular emergencies.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult males after intravenous bolus administration.</p><h4>References</h4><ol><li><p>Twiner, MJ, et al., &amp; Levy, PD (2022). Nitroglycerin Use in the Emergency Department: Current Perspectives. <i>Open access emergency medicine : OAEM</i> 14 327–333. DOI:<a href=&quot;https://doi.org/10.2147/OAEM.S340513&quot;>10.2147/OAEM.S340513</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35847764/&quot;>https://pubmed.ncbi.nlm.nih.gov/35847764</a></p></li><li><p>Sorkin, EM, et al., &amp; Romankiewicz, JA (1984). Intravenous glyceryl trinitrate (nitroglycerin). A review of its pharmacological properties and therapeutic efficacy. <i>Drugs</i> 27(1) 45–80. DOI:<a href=&quot;https://doi.org/10.2165/00003495-198427010-00003&quot;>10.2165/00003495-198427010-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6420139/&quot;>https://pubmed.ncbi.nlm.nih.gov/6420139</a></p></li><li><p>Bogaert, MG (1987). Clinical pharmacokinetics of glyceryl trinitrate following the use of systemic and topical preparations. <i>Clinical pharmacokinetics</i> 12(1) 1–11. DOI:<a href=&quot;https://doi.org/10.2165/00003088-198712010-00001&quot;>10.2165/00003088-198712010-00001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3102143/&quot;>https://pubmed.ncbi.nlm.nih.gov/3102143</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C01DA02;
